(Albany, US) DelveInsight has launched a new report on Epidermolysis Bullosa Pipeline
“Epidermolysis Bullosa Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Epidermolysis Bullosa market. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Epidermolysis Bullosa treatment guidelines. The assessment part of the report embraces in-depth Epidermolysis Bullosa commercial assessment and clinical assessment of the Epidermolysis Bullosa pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Epidermolysis Bullosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. There are various types and subtypes of EB defined by its mode of transmission and a combination of phenotypic, ultrastructural, immunohistochemical, and molecular findings. As per the most recent classification, EB is broadly classified into: EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB), and Kindler syndrome.
Request for free sample page: – https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Epidermolysis Bullosa Pipeline development activities
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Epidermolysis Bullosa Pipeline
With the launch of emerging therapies that includes FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx); AP-101 (Amryt Pharma), allo-APZ2-EB (RHEACELL GmbH & Co. KG), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and Ex-vivo expanded autologous with a COL7A1-encoding retroviral vector and LAMB3 encoding gene therapy (Holostem Terapie Avanzate), the market of EB is anticipated to change during the forecasted period (2020–2030).
Fibrocell is developing a gene therapy candidate for the treatment of RDEB. Fibrocell is developing FCX-007 in collaboration with Intrexon, a leader in synthetic biology. In addition, Fibrocell is working in collaboration with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 for the treatment of RDEB. FCX-007 consists of dermal fibroblasts or skin cells that produce extracellular matrix proteins, including collagen. Fibrocell collects fibroblasts from a patient, then modifies them. Currently, it is being investigated in phase I/II clinical trial, although the interim results from the trial were presented by M. Peter Marinkovich, MD, the trial’s study director at Stanford University, at the 2018 International Investigative Dermatology meeting, held in Orlando, Florida. But in late July 2019, Fibrocell initiated the Phase III clinical trial of FCX-007.
CCP-020 (Diacerein 1% Ointment) is a topical ointment that is being developed by Castle Creek Pharmaceuticals for the treatment of Epidermolysis Bullosa Simplex (EBS). The drug is engineered to potentially block the activity of interleukin-1β (IL-1β), a pro-inflammatory cytokine that is involved in the inflammatory signaling pathway associated with EBS. Blocking of IL-1β reduces the auto-inflammatory effects in the skin of patients with EBS and strengthen epidermal tissue and support healing. Presently Castle Creek Pharmaceuticals is developing CCP-020 is in the Phase II stage of development. CCP-020 is the only drug that is being investigated in EBS so it is expected to cover a major market share as it has no competition.
KB103 (Bercolagene Telserpavec) is Krystal’s lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. The company also intends to develop KB103 as a potential treatment for recessive dystrophic epidermolysis bullosa — the most severe form of DEB — as well as dominant dystrophic epidermolysis bullosa, the disease’s milder form. Currently, Krystal Biotech is investigating KB103 in phase II and III clinical trial to restore functional collagen VII for the treatment of dystrophic epidermolysis bullosa.
According to DelveInsight’s analysis, among all these gene therapies that are under development, KB103will cover major market share. KB103 is under development for DEB and RDEB.
Emerging drugs included in the report
Epidermolysis Bullosa Report Scope
Download free sample page: – https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Table of content
1. Report Introduction
2. Epidermolysis Bullosa
3. Epidermolysis Bullosa Current Treatment Patterns
4. Epidermolysis Bullosa – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Epidermolysis Bullosa Late Stage Products (Phase-III)
7. Epidermolysis Bullosa Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Epidermolysis Bullosa Discontinued Products
13. Epidermolysis Bullosa Product Profiles
14. Epidermolysis Bullosa Key Companies
15. Epidermolysis Bullosa Key Products
16. Dormant and Discontinued Products
17. Epidermolysis Bullosa Unmet Needs
18. Epidermolysis Bullosa Future Perspectives
19. Epidermolysis Bullosa Analyst Review
20. Appendix
21. Report Methodology
Related Reports
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Shruti Thakur
[email protected]
+91-9650213330
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/